These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 20304062)

  • 1. A novel nonsecosteroidal VDR agonist (CH5036249) exhibits efficacy in a spontaneous benign prostatic hyperplasia beagle model.
    Taniguchi K; Katagiri K; Kashiwagi H; Harada S; Sugimoto Y; Shimizu Y; Arakawa H; Ito T; Yamazaki M; Watanabe T; Kato A; Hoshino E; Takahashi T; Esaki T; Suzuki M; Takeda S; Ichikawa F; Harada A; Sekiguchi N; Ishigai M; Kawata H; Yoneya T; Onuma E; Sudoh M; Aoki Y
    J Steroid Biochem Mol Biol; 2010 Jul; 121(1-2):204-7. PubMed ID: 20304062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A series of nonsecosteroidal vitamin D receptor agonists for osteoporosis therapy.
    Kashiwagi H; Ono Y; Ohta M; Itoh S; Ichikawa F; Harada S; Takeda S; Sekiguchi N; Ishigai M; Takahashi T
    Bioorg Med Chem; 2013 Apr; 21(7):1823-33. PubMed ID: 23453218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol).
    Adorini L; Penna G; Amuchastegui S; Cossetti C; Aquilano F; Mariani R; Fibbi B; Morelli A; Uskokovic M; Colli E; Maggi M
    J Steroid Biochem Mol Biol; 2007 Mar; 103(3-5):689-93. PubMed ID: 17241782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol).
    Maggi M; Crescioli C; Morelli A; Colli E; Adorini L
    J Endocrinol Invest; 2006; 29(7):665-74. PubMed ID: 16957418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways.
    Penna G; Fibbi B; Amuchastegui S; Corsiero E; Laverny G; Silvestrini E; Chavalmane A; Morelli A; Sarchielli E; Vannelli GB; Gacci M; Colli E; Maggi M; Adorini L
    Prostate; 2009 Apr; 69(5):480-93. PubMed ID: 19107880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia.
    Fibbi B; Penna G; Morelli A; Adorini L; Maggi M
    Int J Androl; 2010 Jun; 33(3):475-88. PubMed ID: 19508330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia.
    Adorini L; Penna G; Fibbi B; Maggi M
    Ann N Y Acad Sci; 2010 Apr; 1193():146-52. PubMed ID: 20398021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3.
    Boehm MF; Fitzgerald P; Zou A; Elgort MG; Bischoff ED; Mere L; Mais DE; Bissonnette RP; Heyman RA; Nadzan AM; Reichman M; Allegretto EA
    Chem Biol; 1999 May; 6(5):265-75. PubMed ID: 10322128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human prostatic urethra expresses vitamin D receptor and responds to vitamin D receptor ligation.
    Comeglio P; Chavalmane AK; Fibbi B; Filippi S; Marchetta M; Marini M; Morelli A; Penna G; Vignozzi L; Vannelli GB; Adorini L; Maggi M
    J Endocrinol Invest; 2010 Nov; 33(10):730-8. PubMed ID: 20386089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Experimental research on spontaneous benign prostatic hyperplasia in old dogs].
    Cai RF; Cui YG; Hua LX; Jia Y; Ma DZ; Wang XH
    Zhonghua Nan Ke Xue; 2003 Dec; 9(9):651-3, 657. PubMed ID: 14727348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of 1,25(OH)2D3, 25OHD3, and EB1089 on cell growth and Vitamin D receptor mRNA and 1alpha-hydroxylase mRNA expression in primary cultures of the canine prostate.
    Kunakornsawat S; Rosol TJ; Capen CC; Omdahl JL; Leroy BE; Inpanbutr N
    J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):409-12. PubMed ID: 15225811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S; Agoulnik IU; Weigel NL
    Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-18 may lead to benign prostatic hyperplasia via thrombospondin-1 production in prostatic smooth muscle cells.
    Hamakawa T; Sasaki S; Shibata Y; Imura M; Kubota Y; Kojima Y; Kohri K
    Prostate; 2014 May; 74(6):590-601. PubMed ID: 24615654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel nonsecosteroidal VDR agonists with phenyl-pyrrolyl pentane skeleton.
    Shen W; Xue J; Zhao Z; Zhang C
    Eur J Med Chem; 2013 Nov; 69():768-78. PubMed ID: 24099996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel nonsecosteroidal VDR ligands with phenyl-pyrrolyl pentane skeleton for cancer therapy.
    Ge Z; Hao M; Xu M; Su Z; Kang Z; Xue L; Zhang C
    Eur J Med Chem; 2016 Jan; 107():48-62. PubMed ID: 26562542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of canine basal cells in prostatic post natal development, induction of hyperplasia, sex hormone-stimulated growth; and the ductal origin of carcinoma.
    Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
    Prostate; 2001 May; 47(3):149-63. PubMed ID: 11351344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursolic acid reduces prostate size and dihydrotestosterone level in a rat model of benign prostatic hyperplasia.
    Shin IS; Lee MY; Jung DY; Seo CS; Ha HK; Shin HK
    Food Chem Toxicol; 2012 Mar; 50(3-4):884-8. PubMed ID: 22266360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma.
    Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
    Prostate; 2001 Aug; 48(3):210-24. PubMed ID: 11494337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells.
    Peehl DM; Skowronski RJ; Leung GK; Wong ST; Stamey TA; Feldman D
    Cancer Res; 1994 Feb; 54(3):805-10. PubMed ID: 7508338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New histopathological experimental model for benign prostatic hyperplasia: stromal hyperplasia in rats.
    Mori F; Oda N; Sakuragi M; Sakakibara F; Kiniwa M; Miyoshi K
    J Urol; 2009 Feb; 181(2):890-8. PubMed ID: 19095262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.